Project Grant P01HL171803
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$5.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $172,800.00 to Brigham & Women's Hospital Inc. to conduct research on the impact of innate immunity on transfusion medicine immunobiology. The key objectives are to define the factors regulating the production and clinical significance of naturally occurring anti-ABO(H) antibodies, which represent a common immunological barrier...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides funding to Northwestern University to conduct research on innate immune triggers of alloantibody induction related to red blood cell (RBC) transfusions. The $1,149,840 grant, awarded on June 1, 2024, will support a 4-year research project to identify the immunostimulatory ligands on stored RBCs that initiate alloimmunization, and...
This $2,543,734 project grant awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand how red blood cells (RBCs) contribute to inflammation associated with cardiopulmonary bypass (CPB) during pediatric heart surgery. The key objectives are to: 1) determine how supraphysiological shear stress in the CPB circuit induces pro-inflammatory changes in RBCs, 2) investigate if CPB promotes...
The federal Project Grant award R01HL169401, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $834,499.00 to The Children's Hospital of Philadelphia (CHOP) to develop a precision medicine approach to red blood cell transfusion therapy for sickle cell disease (SCD). The key aims are: 1) Providing RH genotype-matched red cells to chronically transfused SCD patients to reduce RH alloimmunization, 2)...
This $395,314 Project Grant award was provided by the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), to The Leland Stanford Junior University. The grant supports research to define the key innate immune cell components and signaling mechanisms that mediate the development of inhibitory antibodies against factor VIII, a critical treatment for hemophilia A. The central hypothesis is that conventional dendritic cells,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $568,264 to SAFI Biotherapeutics Inc. to develop a scalable bioprocess for manufacturing induced pluripotent stem cell (iPSC)-derived red blood cells (RBCs). The goal is to create a renewable source of designer RBCs with unique antigenic profiles to facilitate the identification of complex antibodies in patients requiring blood...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $1,123,357 to support an extensive research program at Childrens Hospital Medical Center in Cincinnati, Ohio. The overarching objective is to define the physiological mechanisms of blood cell production within the bone marrow microenvironment, with a focus on understanding how specialized vascular structures regulate...
This $2,647,283 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to advance understanding of the role of B cells in immune responses and transplant rejection. The primary objectives are to: Further define the transcriptome and regulatory pathways of pro-inflammatory effector B cells (BEff) marked by the TIM-4 receptor, including how they counter-regulate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $234,000.00 in funding to the University of Colorado-Denver. The objective is to engineer hemostatic red blood cells (T-RBCs) that can adhere to collagen and fibrin at bleeding sites, thereby plugging and stopping non-compressible hemorrhage. The project aims to synthesize the T-RBCs, test their ability to enhance clot formation and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,594,544 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The 5-year grant, awarded on September 21, 2024, supports research on how mucin-degrading intestinal bacteria contribute to intestinal graft-versus-host disease (GVHD) and neutropenic fever in patients undergoing allogeneic hematopoietic cell transplantation (allo HCT). The grant supports 3...